Effect of interleukin-1β treatment on co-cultures of human meniscus cells and bone marrow mesenchymal stromal cells by Anika Chowdhury et al.
Effect of interleukin-1β treatment on co-cultures
of human meniscus cells and bone marrow
mesenchymal stromal cells
Chowdhury et al.
Chowdhury et al. BMC Musculoskeletal Disorders 2013, 14:216
http://www.biomedcentral.com/1471-2474/14/216
Chowdhury et al. BMC Musculoskeletal Disorders 2013, 14:216
http://www.biomedcentral.com/1471-2474/14/216RESEARCH ARTICLE Open AccessEffect of interleukin-1β treatment on co-cultures
of human meniscus cells and bone marrow
mesenchymal stromal cells
Anika Chowdhury†, Louis W Bezuidenhout†, Aillette Mulet-Sierra, Nadr M Jomha and Adetola B Adesida*Abstract
Background: Interleukin-1β (IL-1β) is a major mediator of local inflammation present in injured joints. In this study,
we aimed at comparing the effect of IL-1β on engineered tissues from MCs, BMSCs and co-cultured MCs and BMSCs.
Methods: We compared the effect of IL-1β in 3 groups: (1) MCs, (2) BMSCs and, (3) co-cultures of MCs and BMSCs. We
selected 1 to 3 ratio of MCs to BMSCs for the co-cultures. Passage two (P2) human BMSCs were obtained from two
donors. Human MCs were isolated from menisci of 4 donors. Mono-cultures of MCs and BMSCs, and co-cultures of MCs
and BMSCs were cultured in chondrogenic medium with TGFβ3, as cell pellets for 14 days. Thereafter, pellets were
cultured for 3 more days in same medium as before with or without IL-1β (500 pg/ml). Pellets were assessed histologically,
biochemically and by RT-PCR for gene expression of aggrecan, sox9, MMP-1, collagens I and II. Statistics was performed
using one-way ANOVA with Tukey’s post-tests.
Results: Co-cultured pellets were the most intensely stained with safranin O and collagen II. Co-cultured pellets had
the highest expression of sox9, collagen I and II. IL-1β treatment slightly reduced the GAG/DNA of co-cultured pellets
but still exceeded the sum of the GAG/DNA from the proportion of MCs and BMSCs in the co-cultured pellets. After
IL-1β treatment, the expression of sox9, collagen I and II in co-cultured pellets was higher compared to their expression in
pure pellets. IL-1β induced MMP-1 expression in mono-cultures of MCs but not significantly in mono-cultures of BMSCs or
in co-cultured pellets. IL-1β induced MMP-13 expression in mono-cultured pellets of BMSCs and in co-cultured pellets.
Conclusions: Co-cultures of MCs and BMSCs resulted in a synergistic production of cartilaginous matrix compared to
mono-cultures of MCs and BMSCs. IL-1β did not abrogate the accumulated GAG matrix in co-cultures but mediated a
decreased mRNA expression of aggrecan, collagen II and Sox9. These results strengthen the combinatorial use of primary
MCs and BMSCs as a cell source for meniscus tissue engineering by demonstrating retention of fibrochondrogenic
phenotype after exposure to IL-1β.
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Tissue engineeringBackground
The meniscus is a semilunar-shaped fibrocartilaginous
tissue located between the femur and the tibia [1,2]. It is
essential for mechanical load distribution, joint stability
and protection of articular cartilage in the knee joint
[3-6]. The biomechanical role of the meniscus is a result
of its extracellular matrix (ECM) [7]. The ECM is* Correspondence: adesida@ualberta.ca
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distribution, and reproduction in any mediumsynthesized entirely by resident meniscus fibrochondrocytes
and it is composed of type I collagen throughout the en-
tire tissue, and type II collagen and proteoglycans in the
avascular inner two-thirds region of the tissue [8,9]. Per-
haps as a consequence of the tissue’s constrained blood
supply, the reparative and regenerative capacity of the me-
niscus is limited and injuries to the avascular portion nat-
urally do not heal. Depending on the extent of avascular
meniscus injuries, partial or total meniscectomy is
performed which is a common procedure. While these
surgeries may alleviate meniscus injury related pain, theyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ated with high incidence of early development of degen-
erative joint disease, such as osteoarthritis (OA) [10-12].
Thus, there is much interest in the development of alter-
native, biological approaches to meniscus repair and re-
generation [13]. Among these, there is considerable
interest in cell-based tissue engineering and regenerative
medicine strategies with the view to generate functional
meniscus substitutes to replace or aid repair of damaged
menisci [14-29]. However, the optimal cell source for
these approaches is yet to be determined [20,24,30]. Nat-
urally, meniscus cells are the obvious choice but the use of
these cells have several drawbacks that include insufficient
numbers of differentiated meniscus cells and loss of ECM-
forming phenotype of in vitro multiplied meniscus cells
[24]. Bone marrow mesenchymal stromal cells (BMSCs)
have also been explored as a cell source for meniscus tis-
sue engineering with the outcome of forming a meniscus-
like fibrocartilage [30,31]. However, BMSCs are susceptible
to undergoing hypertrophic differentiation [32]. Recent
findings in our laboratory and others demonstrated that
co-culture of primary human meniscus cells with BMSCs
in the presence of chondrogenic factors resulted not only
in a synergistically enhanced production of meniscus-like
ECM and fibrocartilage tissue-like formation, but addi-
tionally the suppression of hypertrophic differentiation of
BMSCs [21,33,34]. Although the mechanism underlying
the synergistic matrix production is to be explored, the
interplay of primary meniscus cells and BMSCs offers the
perspective of delivering a combinatorial cell source for
meniscus reconstruction, with the benefit of retention of
the matrix-forming phenotype of differentiated meniscus
cells and enhanced functional matrix production. How-
ever, for the combination of primary human meniscus
cells and BMSCs to be considered as a cell source for the
generation of functional meniscal grafts, it is important to
evaluate their response to mediators of inflammation,
which are typically present in injured joints or as a conse-
quence of the iatrogenic trauma of the meniscus repair
surgery itself. Pro-inflammatory cytokines, such as
interleukin-1β (IL-1β), are major mediators of local in-
flammation and are known to be present in injured joints.
In the present study, we aimed at studying the effect of IL-
1β on engineered tissues from meniscus cells (MC),
BMSCs and co-cultured MCs and BMSCs. We compared
the effect of IL-1β in three study groups: (1) MCs, (2)
BMSCs and, (3) co-cultures of MCs and BMSCs. For the
co-cultured cell group, we selected a 1 to 3 ratio of MCs
to BMSCs. Our previous work showed that this ratio re-
producibly resulted in synergistic matrix formation after
in vitro chondrogenic differentiation in 3D culture using
the pellet model of mesenchymal cell condensation [21].
We hypothesized that co-cultured MCs and BMSCs will
retain an enhanced chondrogenic matrix-forming capacitycompared to mono-cultured MCs and mono-cultured
BMSCs after short-term treatment with IL-1β.
Methods
Collection of bone marrow specimens and culture of
bone marrow stem cells
Local ethical committee approval of the University of
Alberta, Edmonton, Canada was obtained for this study.
Bone marrow aspirates were acquired during routine
orthopaedic procedures from the iliac crest of two male
donors (age 45 and 57 years). The number of mononu-
cleated cells (MNCs) in the aspirates was determined by
crystal violet nuclei staining and cell counting on a
haemocytometer. Thereafter, 15 million MNCs were
seeded per 150 cm2 tissue culture flask. Culture media
was alpha MEM supplemented with 10% heat inac-
tivated fetal bovine serum, 1 mM sodium pyruvate, 100
mM HEPES buffer, 1 mM sodium pyruvate, 100 U/ml
penicillin, 100 μg/ml streptomycin, 0.29 mg/ml L-
glutamine (all from Invitrogen, Mississauga, Ontario,
Canada) and 5 ng/ml of basic FGF or FGF-2
(Neuromics, Edina, MN, USA). Plastic adherent MNCs
were allowed to attach and proliferate for 7 days before
the first media change under normal oxygen tension
(21% O2; 95% air) at 37°C in a humidified incubator
with 5% CO2. Thereafter, media change was imple-
mented twice per week until 70-80% cell confluence
was attained. The plastic adherent MNCs populations
now termed bone marrow mesenchymal stromal cells
(BMSCs) were detached using trypsin-EDTA (0.05% w/v)
and expanded until passage 2 prior to experimental use.
We characterized the BMSCs as we have previously de-
scribed using a panel of cell surface markers and flow cy-
tometry analysis [35].
Human menisci and meniscus cells isolation
Local ethical committee approval of the University of
Alberta, Edmonton, Canada was obtained to acquire
menisci for this study. Both lateral and medial menisci
were harvested from the knee joint of 4 male donors
(age 56–76, mean age 66 ± 9 years) undergoing total
knee arthroplasty because of osteoarthritis. Meniscus
cells (MCs) were released via treatment with type II col-
lagenase (0.15% w/v; Worthington, Lakewood, NJ, USA)
after 16 h digestion of tissue at 37°C in a standard
medium- high glucose Dulbecco’s modified Eagle’s
medium containing 4.5 mg/ml D-Glucose (DMEM-HG),
0.1 mM non-essential amino acids, 1 mM sodium pyru-
vate, 100 mM HEPES buffer, 1 mM sodium pyruvate,
100U/ml penicillin, 100 μg/ml streptomycin, 0.29 mg/ml
L-glutamine supplemented with 10% FBS - (all from
Invitrogen, Mississauga, Ontario, Canada). The cell sus-
pension obtained after digestion was passed through a
70 μm nylon-mesh filter. Isolated cells were plated at
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under normal oxygen tension (21% O2; 95% air) at 37°C
in a humidified incubator with 5% CO2 before experi-
mental use. Non-adherent cells were aspirated off while
adherent cells were detached with trypsin-EDTA (0.05%
w/v) (from Invitrogen).
Chondrogenic differentiation in pellet cultures
Mono-cultures of MCs and BMSCs in the form of pel-
lets were formed in 250 μl of serum-free chondrogenic
culture medium consisting of standard medium supple-
mented with 0.1 mM ascorbic acid 2-phosphate, 10-5 M
dexamethasone, 1× ITS + 1 premix (Sigma-Aldrich,
Oakville, Canada), 10 ng/ml TGF-β3 (Humanzyme-
Medicorp Inc.) as described previously [36]. A total of
2.5 × 105 cells were spun in 1.5 ml sterile conical polypro-
pylene microfuge tubes (Enzymax LLC, Kentucky, USA)
at 1500 rpm (433 g) for 3 minutes to form spherical cell
pellets. Co-cultures in pellet form consisting of MCs:
BMSCs were formulated by mixing the two cell types at a
1:3 ratio, respectively. Briefly, for each co-cultured pellet
we mixed 62, 500 primary (unexpanded) meniscus cells
with 187, 500 BMSCs at passage 2 (in vitro expanded
cells). Primary meniscus cells from two donors were co-
cultured with BMSCs at passage 2 from one donor and
primary meniscus cells from the other two others were
co-cultured with BMSCs at passage 2 from the other bone
marrow aspirate donor. Control pellets were formed from
either pure primary meniscus cells or pure BMSC (at pas-
sage 2) at cell density of 250,000 per pellet. Previous stud-
ies had shown that the co-cultured cell-cell ratio
reproducibly resulted in enhanced matrix formation
[21]. For each group, a minimum of six pellets were
formed for subsequent histological, biochemical and
molecular analysis. After 2 weeks of pellet culture
with media changes 2 times per week, the pellets
were cultured for 3 additional days in chondrogenic
culture medium in the presence (i.e. MC+, BMSC+
and MC:BMSC+) or absence (i.e. MC, BMSC and MC:
BMSC) of 500 pg/ml of interleukin-1β (Humanzyme-
Medicorp Inc.). After the culture period, pellets were
processed biochemically for GAG and DNA contents, his-
tologically, immuno-histochemically and by real-time
quantitative RT-PCR for gene expression analyses. For
each experimental repeat (4 in total), there was 1 experi-
mental group (co-culture of MC:BMSC+) and 5 control
groups (1 co-culture of MC:BMSC and 4 mono-cultures
of BMSC; BMSC+; MC; MC+). In total there were 24 pel-
lets per each group.
Biochemical analysis
Pellets were rinsed in phosphate buffer saline (PBS;
Invitrogen) prior to 16 h digestion in 250 μl of protein-
ase K (1 mg/ml in 50 mM Tris with 1 mM EDTA,1 mM iodoacetamide and 10 mg/ml pepstatin A – all
from Sigma-Aldrich) at 56°C. The media collected in the
last 3 days of pellet culture was analysed for GAG content.
GAG contents in pellets and the collected media were
measured spectrophotometrically after reaction with 1,9-
dimethylmethylene blue binding (Sigma-Aldrich), with
chondroitin sulfate (Sigma-Aldrich) as a standard [37].
The DNA content was determined spectrofluorometrically
using the CyQuant cell proliferation assay kit (Invitrogen)
with supplied bacteriophage λ DNA as standard. Based on
experimental GAG per DNA values of mono-cultures of
BMSC or MC pellets, the calculated GAG per DNA values
were calculated as a linear function of the proportion (%)






If the calculated GAG/DNA is significantly less than
the experimentally determined GAG/DNA value of co-
cultured pellets, then a synergistically enhanced chon-
drogenic GAG matrix formation is considered to have
taken place [36].
Histology and Immuno-histochemical analyses
Tissues generated from the pellet cultures were fixed in
4% (v/v) phosphate buffered formalin, processed into
paraffin wax, sectioned at 5 μm and stained with 0.1%
(w/v) Safranin O and counterstained with 1% (w/v) Fast
Green stain, to reveal sulfated proteoglycan (GAG)
matrix depositions. Other sections were probed with
antibodies raised against collagen types I and II. Sections
were digested with trypsin and then incubated with anti-
bodies against collagen II (II-II6B3) from Developmental
Studies Hybridoma Bank at University of Iowa, USA.
Immuno-localised antigens were visualized with goat
anti-mouse IgG biotinylated secondary antibody (Dako
Canada Inc., Mississauga, Ontario, Canada) and a
streptavidin-horseradish peroxidase labeling kit with
3,3′-diaminobenzidine (Dako). Images were captured on
an Omano OM159T biological trinocular microscope
(Microscope Store, Virginia, USA) fitted with an
Optixcam summit series 5MP digital camera and
Optixcam software and assembled in Adobe Photoshop
(Adobe Systems Inc. San Jose, USA).
Real-time quantitative RT-PCR assays
Total RNA was extracted from pellets using Trizol
(Invitrogen) after grinding with Molecular Grinding
Resin (Geno Technology Inc. St Louis, USA) in combina-
tion with the use of RNeasy mini kit (Qiagen, Mississauga,
Ontario, Canada) and after removal of contaminating gen-
omic DNA from the pellets by DNase treatment. To
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harvest, cell pellets were immediately (< 1 min) transferred
into Trizol. Total RNA (100 ng) in a 40 μl reaction was
reverse transcribed to cDNA using GoScript reverse
transcriptase) primed with oligo(dT)15 primer (Fisher
Scientific, Whitby, Ontario, Canada). Quantitative real-
time polymerase chain reaction (qRT-PCR) was performed
in DNA Engine Opticon II Continuous Fluorescence De-
tection System (Bio-Rad) using hot start Taq and SYBR
Green detection (Eurogentec North America Inc., San
Diego, CA, USA). Primer sequences for aggrecan (AGG),
collagen I (COL1A2), collagen II (COL2A1), collagen X
(COL10A1), interleukin 1 receptor antagonist (IL1Ra),
matrix metalloproteinase −1 (MMP-1), matrix metal-
loproteinase −2 (MMP-2), matrix metalloproteinase −13
(MMP-13), SOX9 and β-actin (Table 1) were taken from
previously published work or were custom designed using
the Primer Express software (Applied Biosystems, Foster
City, USA) [38-40]. All primers were obtained from
Invitrogen. For each cDNA sample, the threshold cycle
(Ct) value of each target gene was reduced by subtrac-
tion of Ct value of human β-actin to derive ΔCt. The
level of gene expression was calculated as 2-Δct [41].
Each sample was assessed at least in triplicates for each
gene of interest.Table 1 Primer sequences used in quantitative real-time





























For each experimental repeat and donor, at least tripli-
cate specimens were assessed and the data were
presented as mean ± standard error of mean (SEM) of
measurements. All statistical analyses were performed
using SPSS version 20 (IBM SPSS Statistics 20; Chicago,
IL, USA) unless stated otherwise. Differences between
experimental groups were assessed by one-way ANOVA
with Tukey’s multiple comparison post-tests and consid-
ered significant with p < 0.05 (i.e. *p < 0.05, ** p < 0.01
and ***p < 0.001).
Results
Enhanced cartilaginous tissue formation in co-cultures of
meniscus cells (MCs) and BMSCs
Firstly, we established that chondrogenic co-culture of
MCs and BMSCs resulted in a synergistically enhanced
cartilaginous matrix formation relative to mono-cultures
of MCs and BMSCs as previously reported [21]. After a
total of 17 days of cell culture in 3D cell pellet format in
the presence of TGFβ3 supplemented chondrogenic
media, primary human MCs, passaged 2 expanded
BMSCs or in co-culture with each other at 1 to 3 ratio,
respectively, formed hyaline-like cartilaginous tissue with
varied staining intensity for GAG (as detected by Safranin
O stain) and collagen II (Figure 1A). Qualitatively, the
GAG and collagen II staining intensity was least in mono-
cultured meniscus cell pellets and highest in co-cultured
cell pellets of MCs and BMSCs. Biochemical analysis for
the accumulated GAG amount after normalization β to
the cellular DNA content, revealed statistically significant
differences between the GAG content of co-cultured
and mono-cultured pellets of MCs (p value of 0.005;
Figure 2A). The GAG/DNA content was 3.40 ± 0.19 μg/μg
(for MCs pellets), 6.43 ± 0.32 μg/μg (for co-cultured MCs:
BMSC pellets) and 6.42 ± 0.30 μg/μg (for mono-cultured
BMSC pellets) (Figure 2A; Table 2).
Effect of IL-1β on cartilaginous tissue formation
in co-cultures of MCs and BMSCs
Addition of IL-1β (500 pg/ml) on day 14 of the 17 days
of chondrogenic pellet culture resulted in tissues with
reduced Safranin O staining appearance relative to con-
trol pellet cultures without IL-1β treatment (Figure 1A
and B). In contrast, the collagen II staining intensity
appeared similar between control and experimental pairs
although there was some evidence of altered distribution
of the matrix protein within pellets. Biochemical analysis
for GAG/DNA content confirmed the reduced GAG
staining intensity in pellets formed from mono-cultured
MCs relative to mono-cultured pellets of BMSCs or co-
cultured pellets of MCs and BMSCs (Table 2). Although
the GAG/DNA value for pellets from mono-cultured
MCs (2.87 ± 0.46 μg/μg) and co-cultured cells (6.11 ±
Figure 1 Histological characteristics of pellets formulated from mono-cultured MCs, mono-cultured BMSCs and co-cultures of MC and
BMSCs after a total of 17 days culture in defined serum-free chondrogenic media. (A-B) Safranin O and collagen II immuno-histochemical
staining of representative pellets from cells derived from the same donor. Magnification lens × 20; scale bar is 100 μm.
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IL-1β treatment, the values were not significantly dif-
ferent (p values of 1.00 and 0.98, respectively) from that
of control pellets (Figure 2A). There was no significant
difference between the GAG/DNA contents of BMSCs
pellets treated with or without IL-1β (p value 1.00;
Figure 2A).Figure 2 Accumulation of cartilaginous matrix in cell pellets after a to
(A) Accumulated glycosaminoglycan (GAG) matrix content of cell pellets n
(SEM) of 4 donors. (B) Comparison of experimental and calculated GAG pe
calculated as per equation given in Methods and Materials sub-section Bio
donor pairs. One-way analysis of variance (ANOVA) with Tukey’s multiple co
(***) indicates p < 0.0001 for statistical significance of comparison.Based on the experimental GAG/DNA values of mono-
cultured MCs and BMSCs, the calculated GAG/DNA
content of co-cultured pellets of MCs and BMSCs was
determined as a linear function of the proportion of
MCs and BMSCs in the co-cultured pellets. In the ab-
sence of IL-1β, the calculated GAG/DNA content was
5.66 ± 0.05 μg/ug, while in the presence of IL-1β thetal of 17 days culture in serum-free chondrogenic media.
ormalized to DNA amount. Data are mean ± standard error of mean
r DNA contents of cells pellets. Calculated GAG per DNA content was
chemical analysis. Data are mean ± standard error of mean (SEM) of 4
mparison post-tests: (*) indicates p <0.05, (**) indicates p < 0.001 and
Table 2 GAG/DNA contents of pellets before and after
treatment with IL-1β
Pellets GAG/DNA (μg/μg) ± SEM* IL-1β (500 pg/ml)
MC 3.40 ± 0.19 -
MC:BMSC 6.43 ± 0.32 -
BMSC 6.42 ± 0.30 -
MC+ 2.87 ± 0.46 +
MC:BMSC+ 6.11 ± 0.31 +
BMSC+ 6.30 ± 0.56 +
*Standard error of mean (SEM).
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The experimentally determined GAG/DNA contents of
the co-cultured pellets were 6.43 ± 0.32 μg/ug, in the ab-
sence of IL-1β, and 6.11 ± 0.31 μg/ug after treatment
with IL-1β. The experimental GAG/DNA value for co-
cultured pellets in the absence of IL-1β was significantly
higher than calculated (1.14-fold; p value of 0.001). Simi-
larly, there was a significant difference (1.12-fold; p value
of 0.002) between the calculated and experimental GAG/
DNA values of the co-cultured pellets after IL-1β treat-
ment i.e. 5.44 ± 0.04 μg/ug (calculated) vs. 6.11 ± 0.31 μg/
ug (experimental) (Figure 2B).
Effect of IL-1β on gene expression profile of cultures of
meniscus cells and BMSCs
We evaluated the expression of a panel of genes (i.e.
aggrecan, collagens I and II, Sox9 that we had previously
reported to be synergistically up-regulated in chon-
drogenic co-cultures of meniscus cells and bone marrow
mesenchymal stromal cells, and the expression collagen
X that had been shown to be down-regulated in co-
cultures of meniscus cells and BMSCs [21,33,34]. Addi-
tionally, we investigated the expression of a panel of
catabolic genes, MMP-1, MMP-3 and MMP-13, which
have been reported to be modulated at both the mRNA
and protein levels by IL-1β in chondrocytes to [42]. Fi-
nally, we investigated the expression of IL1Ra as it had
been shown to mediate the anti-inflammatory and anti-
fibrotic response of BMSCs to IL-1α in the lungs of
mice, and inhibition of IL-1β mediated matrix degrad-
ation in human intervertebral discs [43,44]. The follow-
ing observations were made in pellets cultured in the
absence or after short term treatment of pellets with IL-
1β: (1) the transcript expression of aggrecan and Sox9
were significantly upregulated in co-cultured pellets than
in mono-cultured pellets of MC in the absence of IL-1β.
The expression of aggrecan and Sox9 in the co-cultured
pellets was not significantly different from their expres-
sion in pure BMSC pellets. However, after short-term
treatment of all pellets with IL-1β, the level of expres-
sion of both genes declined (relative to pellets without
IL-1β treatment) to levels that were not statisticallydifferent between the different pellet groups (Figure 3A
and B); (2) in the absence of IL-1β, the expression of col-
lagen I was significantly higher in co-cultured pellets
relative to its expression in mono-cultured pellets. After
IL-1β treatment, the expression of collagen I declined in
all pellets groups, however, its expression (although de-
creased) remained significantly higher in the co-cultured
pellets than in pure MC pellets. In contrast, collagen I’s
expression was similar in co-cultured pellets and pure
BMSCs pellets after IL-1β treatment (Figure 3C). Simi-
larly, the expression of collagen II was significantly
higher in the co-cultured pellets compared to its expres-
sion in either pure MC or pure BMSC pellets in the ab-
sence of IL-1β. After treatment of all pellets with IL-1β,
the expression of collagen II declined relative to control
pellets without IL-1β treatment but its expression
remained significantly higher in the co-cultured pellets
relative to its expression in pure MC and pure BMSCs
pellets (Figure 3D); (3) in the absence of IL-1β, the level
of collagen X expression in pure BMSC and co-cultured
pellets was significantly higher (26-fold; p value of 0.001)
than its expression in pure MC pellets. In contrast, the
expression of collagen X decreased to the same level in
both co-cultured and mono-cultured pellets of BMSC
after IL-1β treatment. Collagen X expression remained
at the same level of expression in MC pellets before and
after treatment with IL-1β (Figure 3E); (4) in the absence
of IL-1β, the level of MMP-1 expression was similar in
all pellets. However, after IL-1β treatment, we observed
a statistically significant (p value of 0.02) increase in
MMP-1 expression in mono-cultured MC pellets relative
to other pellets (Figure 3F). Additionally, MMP-1 ex-
pression was significantly up-regulated (21-fold; p value
of 0.006) in co-cultured cell pellets after IL-1β treatment
relative to co-cultured controls without IL-1β treatment
(Figure 3F). In contrast, the level of MMP-3 expression
remained the same in all pellets before and after treat-
ment with IL-1β (Figure 3G). The expression of MMP-
13 in pure MC pellets was not significantly modulated by
IL-1β. However, IL-1β increased the expression of MMP-
13 in pure BMSC and co-cultured pellets (Figure 3H).
The expression of IL1Ra was highest in co-cultured pellets
without IL-1β treatment (Figure 3I). After treatment with
IL-1β, the expression of IL1Ra declined significantly by
24-fold in co-cultured pellets relative to its expression in
co-cultured pellets without IL-1β treatment. IL-1β did not
significantly modulate the expression of IL1Ra in pure
MC or pure BMSC (Figure 3I).
Discussion
Previously we showed that co-culture of primary human
MCs with BMSCs formed tissue with a fibrocartilage
phenotype and a synergistically enhanced GAG matrix con-
tent relative to mono-cultured MCs and mono-cultured
Figure 3 Gene expression analysis via quantitative real time RT-PCR. mRNA gene expression analysis via SYBR Green detection was used to
evaluate gene expression of: (A) aggrecan, (B) sox9, (C) collagen I (COL1A2), (D) collagen II (COL2A1), (E) collagen X (COL10A1) (F) matrix
metalloproteinase-1 (MMP-1), (G) matrix metalloproteinase −3 (MMP3), (H) matrix metalloproteinase-13 (MMP13), and (I) interleukin 1 receptor
antagonist (IL1Ra) in pellets from MCs, MC:BMSCs and BMSCs after 17 days of culture in serum free chondrogenic medium containing TGF-β3,
dexamethasone and ascorbate. In the last 3 days of pellet culture, pellets were either cultured in the presence (signified by +) or absence of IL-1β.
Each data point represents the mean ± SEM. One-way analysis of variance (ANOVA) with Tukey’s multiple comparison post-tests was performed using
SPSS version 20 and statistical significance level indicators are: *p <0.05, **p <0.01; *** p <0.0001. No significant (ns) difference. All marker gene
expression data was normalized to expression of human β-actin; y-axis.
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Similar findings were also reported by Cui et al. [34]. In
this study we evaluated and compared the response of
co-cultured MCs and BMSCs in 3D pellets, as well as
mono-cultured MC and mono-cultured BMSC pellets, to
short-term treatment of IL-1β. In the absence of IL-1β,
we observed significant increase in the GAG matrix-
forming capacity of co-cultured MCs and BMSCs pellets
relative to control mono-cultured pellets of MCs and
BMSCs. In the presence of IL-1β, the GAG matrix-
forming capacity of both co-cultured cells and mono-
cultured MCs decreased slightly but not significantly
compared to their control without IL-1β. Similarly, the
GAG matrix-forming capacity of mono-cultured BMSCs
decreased slightly (relative to control BMSCs) after treat-
ment with IL-1β. Based on the proportion of MCs and
BMSCs in the co-cultured pellets and the GAG matrixper DNA of mono-cultured MCs and mono-cultured
BMSCs, the experimentally determined amount of GAG
matrix per DNA in the co-cultured pellets significantly
exceeded expectation in the absence of IL-1β. A similar
outcome occurred after short term treatment of co-
cultured pellets with IL-1β; the experimentally determined
amount of GAG matrix per DNA in the co-cultured pel-
lets exceeded the expected GAG per DNA content. This
finding suggested that the synergistic interplay between
MCs and BMSCs was retained after short term treatment
of pellets with IL-1β. While the mechanism underlying
the interplay of MCs and BMSCs in the presence of IL-1β
was not investigated in this study, it appears to be associ-
ated with increased transcription of MMP-1 and MMP-13,
and perhaps MMP-1 and MMP-13 mediated matrix re-
modelling. Having said that, based on histological and
gene expression findings in this study, it is reasonable to
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pellets to IL-1β treatment is dependent on the differential
effects of IL-1β on the MCs and BMSCs components of
the co-cultured pellet. For example, safranin O staining
was lost in mono-cultured MCs pellets after IL-1β treat-
ment, while mono-cultured BMSCs pellets retained some
of its positive safranin O staining for GAG matrix. Addi-
tionally, after IL-1β treatment, there was a highly sig-
nificant increase (7-fold) in MMP-1 expression in
mono-cultured MCs relative to controls, while IL-1β had
little or no inductive effect on mono-cultured BMSCs’
MMP-1 expression. This suggests that the significant up-
regulation in MMP-1 expression in co-cultured pellets
was due to the MCs component of the co-culture. Fur-
thermore, IL-1β modulated the expression of MMP-13 in
the BMSCs component (but not in MC component) of
the co-cultured pellets and perhaps more synergistically in
the presence of MC as evaluated in the co-cultured pellets.
Nevertheless, our findings are consistent with the effect of
IL-1β on engineered tissues from meniscus-like cells (i.e.
cell-culture expanded nasal and articular chondrocytes)
that MMP-1 expression was enhanced and accompanied
by decreased GAG matrix-forming capacity [42,45]. How-
ever, it was surprising that IL-1β did not modulate the ex-
pression of MMP-3 in mono-cultured pellets of MCs or in
the co-cultured pellets since Lemke et al. [46], although
with a different IL-1 isoform, had reported increased
MMP-3 mRNA expression post IL-1α treatment of bovine
meniscus explants.
Additionally, our data showed that the GAG/DNA
contents of mono-cultured pellets of MCs declined after
treatment with IL-1β and this finding was consistent
with a reduction or loss of safranin O staining. However,
a similar finding was absent in mono-cultured BMSCs
and in co-cultured MC and BMSC pellets where a rela-
tively more visible and positive staining of safranin O
remained post IL-1β treatment. The reason for this is
unclear but may be associated with a significantly higher
expression of interleukin 1 receptor antagonist (IL1Ra)
in the co-cultured or BMSC pellets relative to MC pel-
lets prior to IL-1β treatment since IL1Ra has been impli-
cated in mitigating the pro-inflammatory effects (i.e.
inflammation and fibrosis) of IL-1α in mice lungs after
treatment with BMSCs [44]. While the potential involve-
ment of IL1Ra needs further investigation, our finding
that collagen I expression was down-regulated in BMSCs
after treatment with IL-1β provides supporting evidence
of its involvement since reduction of collagen I expres-
sion is a characteristic feature of anti-fibrosis [47].
Although the fibrogenic (COL1A2) and chondrogenic
(AGG, COL2A1 and Sox9) mRNA expression of the co-
cultured cell pellets declined after IL-1β treatment, our
data demonstrated that a synergistically enhanced
chondrogenic GAG matrix formation remained in theco-cultured pellets even after treatment with IL-1β. The
reason for this disparity may be a time lag between tran-
scription and translation of genes [48], or alternatively
that the 72 hour treatment of pellets with IL-1β was not
a sufficient timeframe to adequately evaluate the turn-
over of GAG matrix accumulated in the co-cultured pel-
lets. Nonetheless, our data is consistent with previous
findings that IL-1β reduces the abundance of mRNAs
encoding COL2A1, aggrecan and Sox9 [49]. Moreover,
our data aligns with previous findings that IL-1β sup-
presses collagen X expression in chondrocytes [50]. Al-
though, for some unknown reason the expression of
collagen X was not suppressed in the absence of IL-1β
post co-culture of MC and BMSCs as we and others
have previously reported [33,34]. On the whole, it is
probable that the down-regulation of the chon-
drogenic genes in our study by IL-1β was mediated
by activation of nuclear factor-KappaB (NF-kB), a
transcription factor known to suppress the synthesis
of Sox9 through post-transcriptional processes that
destabilize Sox9 mRNA [51,52].
Conclusions
This study showed that: (1) chondrogenic co-cultures of
primary MCs and BMSCs led to the formation of a neo-
tissue that was characterized by enhanced production of
GAG matrix relative to mono-cultures of pure MCs and
pure BMSCs; (2) short term treatment of the chon-
drogenic co-cultures of MCs and BMSCs with IL-1β
resulted in a neo-tissue characterized by a GAG matrix
content that was consistent with more than the sum of
the GAG matrix produced by the proportion of MCs
and BMSCs in the co-cultured pellets; (3) the tissue
formed by co-cultured MCs and BMSCs even after treat-
ment with IL-1β had a phenotype (based on collagen I
and II gene expression data) that was more consistent
with meniscus fibrocartilage than tissues formed from
mono-cultures of MCs and BMSCs. Thus, our findings
strengthen the use of co-cultured primary MCs and
BMSCs as a combinatorial cell source for meniscus tis-
sue engineering.
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